Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COO 
The Cooper Companies, Inc (COO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: COO (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $93.03
1 Year Target Price $93.03
| 9 | Strong Buy |
| 2 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.16% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.53B USD | Price to earnings Ratio 35.17 | 1Y Target Price 93.03 |
Price to earnings Ratio 35.17 | 1Y Target Price 93.03 | ||
Volume (30-day avg) 19 | Beta 0.99 | 52 Weeks Range 65.00 - 112.38 | Updated Date 07/1/2025 |
52 Weeks Range 65.00 - 112.38 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.39% | Operating Margin (TTM) 18.44% |
Management Effectiveness
Return on Assets (TTM) 3.88% | Return on Equity (TTM) 5.15% |
Valuation
Trailing PE 35.17 | Forward PE 17.45 | Enterprise Value 16668504909 | Price to Sales(TTM) 3.64 |
Enterprise Value 16668504909 | Price to Sales(TTM) 3.64 | ||
Enterprise Value to Revenue 4.18 | Enterprise Value to EBITDA 15.16 | Shares Outstanding 199512992 | Shares Floating 198137863 |
Shares Outstanding 199512992 | Shares Floating 198137863 | ||
Percent Insiders 0.62 | Percent Institutions 102.58 |
Upturn AI SWOT
The Cooper Companies, Inc
Company Overview
History and Background
Founded in 1958 as Martin H. Smith Company, renamed Cooper Laboratories in 1967. Focused on healthcare products, later specializing in vision care and women's health. Evolved through strategic acquisitions and divestitures.
Core Business Areas
- CooperVision: Manufactures and markets a wide range of soft contact lenses, including spherical, toric, multifocal, and specialty lenses. Caters to various vision correction needs.
- CooperSurgical: Offers a diverse portfolio of products and services focused on women's health, including fertility solutions, diagnostics, and surgical instruments. Addresses needs throughout a woman's reproductive life cycle.
Leadership and Structure
CEO: Albert White III. Operates with a functional organizational structure across its two main business segments, supporting global operations.
Top Products and Market Share
Key Offerings
- MyDay Daily Disposable: Daily disposable contact lenses offering comfort and vision correction. Competitors: Alcon's Dailies, Johnson & Johnson's Acuvue. Difficult to extract exact revenue, market share is growing in the daily disposables segment.
- Avaira Vitality: Monthly silicone hydrogel contact lenses. Competitors: Bausch + Lomb's Ultra, Alcon's Air Optix. The product drives significant revenue in the monthly reusable contact lens segment.
- Paragard IUD: A non-hormonal intrauterine device for long-term contraception. Competitors: Bayer's Mirena, Kyleena, Skyla. Market share within IUD market is considerable.
- Origio: Fertility solutions including IVF media and equipment. Competitors: Vitrolife, Cook Medical. Significant revenue in the fertility solutions market.
Market Dynamics
Industry Overview
The vision care market is driven by increasing prevalence of refractive errors and aging populations. The women's health market is growing due to increased focus on reproductive health and fertility treatments.
Positioning
CooperCompanies holds a strong position in both the contact lens and women's health markets. Competitive advantages include a diverse product portfolio, strong brand recognition, and a global distribution network.
Total Addressable Market (TAM)
The global contact lens market is projected to reach $14.5 billion by 2028. The women's health market is even larger, estimated around $40 billion. CooperCompanies captures a significant portion but has growth potential in both areas.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Strong brand recognition
- Global distribution network
- Innovation in specialty lenses and fertility solutions
- Solid financial performance
Weaknesses
- Dependence on key products
- Exposure to regulatory risks
- Integration challenges with acquisitions
- Currency fluctuations affecting international revenue
- Competition from larger players
Opportunities
- Expanding into emerging markets
- Developing new contact lens technologies
- Acquiring complementary businesses
- Increasing focus on digital health solutions
- Growth in fertility treatments
Threats
- Increased competition
- Technological disruptions
- Economic downturns
- Changes in healthcare regulations
- Product liability claims
Competitors and Market Share
Key Competitors
- JNJ
- ALC
- BHC
Competitive Landscape
CooperCompanies faces competition from larger players like Johnson & Johnson and Alcon, but differentiates itself through its specialty lens offerings and focus on women's health.
Major Acquisitions
Generate Life Sciences
- Year: 2021
- Acquisition Price (USD millions): 1600
- Strategic Rationale: Expanded CooperSurgical's portfolio of fertility solutions.
Growth Trajectory and Initiatives
Historical Growth: The Cooper Companies has demonstrated steady growth through organic initiatives and strategic acquisitions.
Future Projections: Analysts project continued revenue growth driven by increasing demand for contact lenses and women's health products.
Recent Initiatives: Recent initiatives include expanding its specialty lens portfolio, investing in digital marketing, and acquiring companies in the fertility space.
Summary
The Cooper Companies demonstrates steady revenue growth, focusing on vision care and women's health. While facing competition from larger companies, its specialty lens offerings and strategic acquisitions drive its market position. Continued investment in innovation and expansion into emerging markets will be crucial for sustained growth. Manageable debt and positive cash flow contributes to the companyu2019s stability. Monitoring regulatory changes and technological advancements is essential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data are estimates and may vary across sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About The Cooper Companies, Inc
Exchange NASDAQ | Headquaters San Ramon, CA, United States | ||
IPO Launch date 1983-12-30 | President, CEO & Non-Independent Director Mr. Albert G. White III | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 16000 | Website https://www.coopercos.com |
Full time employees 16000 | Website https://www.coopercos.com | ||
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia; and spherical lense, including lenses that correct near and farsightedness in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including paragard contraceptive intrauterine devices; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.